Trial Profile
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ezetimibe/rosuvastatin (Primary) ; Rosuvastatin
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Shin Poong Pharmaceutical
- 29 May 2018 Primary endpoint (Percent change from baseline to 8 week in LDL-Cholesterol) has been met, according to the Results published in the Clinical Therapeutics
- 29 May 2018 Results of the main study and the extension study, published in the Clinical Therapeutics
- 22 Sep 2017 New trial record